Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
Date:2/7/2013

JERSEY CITY, N.J., Feb. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced it will report fourth quarter and fiscal year 2012 financial results after the NASDAQ Global Market closes on February 28. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada.  Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.  The Company is exploring marketing authorization in other parts of th
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
9. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
11. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... & Gamble Company (NYSE: PG ) today announced ... Advisory Panel (SEAP). The new members are: ... Dr. Howard Frumkin – Dean, School of the Public ... Former Secretary, California Environmental Protection Agency ...
... 2011 Following through with plans to expand its Medical ... Florida. Currently operating on a fee for service basis, OMI ... the state. IMD Companies anticipates that OMI will be servicing ... of time. ABOUT IMD COMPANIES, INC. ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3IMD Companies, Inc. Announces OMI Operations in Florida 2
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... 2014 Visual Impact Frequency Training ... been released to the public generating a frenzied ... and fitness community. The commotion surrounding the program's ... Delmonico prompting an investigative review. , "Many gym-goers ... is commonly known as a training 'plateau' where ...
(Date:10/19/2014)... October 19, 2014 The federal ... continuing to move forward in Massachusetts federal court, ... filed over the dialysis medication, Bernstein Liebhard LLP ... October 15th shows 2,127 claims now filed over ... in the U.S. District Court, District of Massachusetts. ...
(Date:10/19/2014)... California (PRWEB) October 19, 2014 Theme and ... plugin for Final Cut Pro X entitled ProSketchy. ... looking text into any video project.” Said Christiana Austin, CEO ... needed to customize their own sketch style text.” , With ... smudged and smeared text all with in Final Cut Pro ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 2Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 3
... , ... ... , ... , , ...
... disease (HD) is a cruel, hereditary condition that leads to ... Currently, there are no treatments to slow down or ... although they do not show symptoms until late in life. ... of Neuroscience , Stephen Ferguson and Fabiola Ribeiro of Robarts ...
... ... supplements has created a brand new market for health supplements, customers who want to ... attention, HGH Supplements like Sytropin. , ... (PRWEB) February 23, 2010 -- Increased positive coverage by respected media ...
... , ... ... ... ...
... ... ... ... ...
... The George Washington University, School of Public Health and Health ... chronic disease, is on the rise in America and released ... surging cost of treatment, and the more than 1 million ... from GW, Changing pO2licy: The Elements for Improving Childhood Asthma ...
Cached Medicine News:Health News:Catholic Health Association Statement on February 25 Health Reform Summit 2Health News:Catholic Health Association Statement on February 25 Health Reform Summit 3Health News:Protecting the brain from a deadly genetic disease 2Health News:Sytropin HGH Shows Promising Anti-Aging Results 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 2Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 3Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 4Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 5Health News:Startling new childhood asthma data 2Health News:Startling new childhood asthma data 3Health News:Startling new childhood asthma data 4
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: